The 20 references in paper O. Kirsanova V., V. Omelyanovsky V., О. Кирсанова В., В. Омельяновский В. (2018) “Анализ проблемы регулирования доступа к биосимилярам и пути решения // Options to optimize the access to biosimilars: analysis and solutions” / spz:neicon:pharmacoeconomics:y:2018:i:1:p:50-55

1
Global Medicines Use in 2020. Outlook and Implications. November
(check this in PDF content)
2
15. URL: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/ global-medicines-use-in-2020.pdf?la=uk-ua&hash=968B71C0B0769A17 9F3A56E331C62754EEF74752. Accessed: 05.01.2018. 2. Sura M. V., Maksimova L. V., Nazarov V. S. Medicinskie tekhnologii. Ocenka i vybor (in Russian). 2013; 2 (12): 73-83.
(check this in PDF content)
3
Overview of public procurement of medicines in the public segment of the pharmaceutical market of medicines (in Russian). URL: https://alpharm.ru/sites/default/files/obzor_gosudarstvennyh_ zakupok_lp_v_gosudarstvennom_segmente_fr_lp_2017.pdf. Accessed: 05.01.2018.
(check this in PDF content)
4
Explanatory Memorandum to the draft Federal law “on amendments to the Federal law” on fundamentals of public health protection in the Russian Federation “ (in terms of treatment of rare (orphan) diseases) (in Russian). URL: http://sozd.parlament.gov.ru. Accessed: 05.01.2018.
(check this in PDF content)
5
Sura M. V., Omelyanovsky V. V., Avksent’eva M. V., Tatarinov A. P., Gerasimova K. V. Medicinskie tekhnologii. Ocenka i vybor (in Russian). 2014; 3 (17): 43-50.
(check this in PDF content)
6
NCD mortality and morbidity URL: http://www.who.int/gho/ncd/ mortality_morbidity/en/. Accessed: 04.01.2018.
(check this in PDF content)
7
The decision of the Board Eurasian economic Commission of 03.11.2016 No. 89 “Rules of studies of biological drugs EAEC» (in Russian). URL: https://www.alta.ru/tamdoc/16sr0089/. Accessed: 11.01.2018.
(check this in PDF content)
8
Sokolov A. V. Medicinskie tekhnologii. Ocenka i vybor (in Russian). 2012; 3 (9): 52-56.
(check this in PDF content)
9
PRACTITIONER’S SECTION. Understanding the market dynamics of biosimilars. Thorsten Daubenfeld, Jonas Dassow, Maximilian Keßler and Jonas Schulze. The Journal of Business Chemistry (JoBC). URL: http://www.businesschemistry.org/ article/?article=218. Accessed: 11.01.2018.
(check this in PDF content)
10
A Systematic Review of U. S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding? URL: https://www.jmcp.org/doi/10.18553/jmcp.2017.23.12.1234. Accessed: 04.01.2018.
(check this in PDF content)
11
The Biosimilars Market. Fri, 10/31/2014 – 11:19 am by Sarfaraz K. Niazi, Ph. D., Founding Chairman and CEO, Therapeutic Proteins International. URL: https://www.pharmpro.com/ article/2014/10/biosimilars-market. Accessed: 11.01.2018.
(check this in PDF content)
12
State laws and legislation related to biologic medications and substitution of biosimilars. URL: http://www.ncsl.org/research/health/ state-laws-and-legislation-related-to-biologic-medications-andsubstitution-of-biosimilars.aspx. Accessed: 04.01.2018.
(check this in PDF content)
13
State laws and legislation related to biologic medications and substitution of biosimilars. URL: http://www.ncsl.org/research/health/ state-laws-and-legislation-related-to-biologic-medications-andsubstitution-of-biosimilars.aspx. Accessed: 04.01.2018.
(check this in PDF content)
14
Federal law “On circulation of drugs” dated 12.04.2010 No 61-FZ (as last revised) (in Russian). URL: http://www.consultant.ru/ document/cons_doc_LAW_99350/. Accessed: 10.01.2018.
(check this in PDF content)
15
The order of the Government of the Russian Federation of 28.10.2015 N 1154 “About the order of determination of interchangeability of medicines for medical application” (together with “ rules of determination of interchangeability of medicines for medical application») (in Russian). URL: http://www.pravo.gov.ru. Accessed: 11.01.2018.
(check this in PDF content)
16
Vorob’ev I. I., Kovnir S. V., Orlova N. A., Khodak Yu. A., Polzikov M. A. Razrabotka i registratsiya lekarstvennykh sredstv (in Russian). 2015; 13: 122-6.
(check this in PDF content)
17
Vorob’ev I. I., Semikhin A. S., Golovina E. O. Akusherstvo, ginekologiya i reproduktsiya / Obstetrics, gynecology and reproduction (in Russian). 2017; 11 (3): 116-126. DOI:10.17749/23137347.2017.11.3.116-126.
(check this in PDF content)
18
Podkorytov A. B., Zhilyaev O. V., Polzikov M. A. Akusherstvo, ginekologiya i reproduktsiya / Obstetrics, gynecology and reproduction. (in Russian). 2017; 11 (4): 35-42. DOI: 10.17749/2313-7347.2017.11.4.035-042.
(check this in PDF content)
19
Biosimilar Versus Originator Insulins: Systematic review and meta-analysis antibodies. URL: http://sci-hub.tw/10.1111/dom.13291. Accessed: 04.01.2018.
(check this in PDF content)
20
Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars». URL: http://sci-hub.tw/https://doi. org/10.1080/14712598.2017.1341486. Accessed: 08.01.2018. Сведения об авторах:
(check this in PDF content)